- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.12.25 | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 2 | SGX Company Announcements | ||
| 13.12.25 | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 1 | SGX Company Announcements | ||
| 11.12.25 | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 1 | SGX Company Announcements | ||
| 08.12.25 | Viatris sells Biocon Biologics stake for $815 million in cash and equity deal | 38 | Seeking Alpha | ||
| BIOCON BIOLOGICS Aktie jetzt für 0€ handeln | |||||
| 06.12.25 | Viatris To Sell Equity Stake In Biocon Biologics To Biocon For $815 Mln | 673 | AFX News | NEW DELHI (dpa-AFX) - Viatris Inc. (VTRS) announced that it has entered into definitive agreements with Biocon Limited for the sale of its equity stake in Biocon Biologics Limited. Under the... ► Artikel lesen | |
| 06.12.25 | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::ANALYST CALL INTIMATION SUBMITTED BY BIOCON LIMITED | 3 | SGX Company Announcements | ||
| 06.12.25 | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 3 | SGX Company Announcements | ||
| 06.12.25 | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::OUTCOME OF BOARD MEETING OF BIOCON LIMITED | 2 | SGX Company Announcements | ||
| 02.12.25 | Biocon Biologics settles with Amgen to launch Denosumab Biosimilars in Europe, rest of the world | 10 | ZEE Business | ||
| 02.12.25 | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 1 | SGX Company Announcements | ||
| 27.11.25 | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::COMPANY STATEMENT | 8 | SGX Company Announcements | ||
| 12.11.25 | BIOCON BIOLOGICS GLOBAL PLC: FINANCIAL STATEMENTS AND RELATED ANNOUNCEMENT::SECOND QUARTER AND/OR HALF YEARLY RESULTS | 3 | SGX Company Announcements | ||
| 11.11.25 | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 1 | SGX Company Announcements | ||
| 23.10.25 | Biocon Biologics Receives Health Canada Approval for Yesintek and Yesintek I.V. (ustekinumab), a Biosimilar to Stelara | 4 | CNW | ||
| 23.10.25 | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 2 | SGX Company Announcements | ||
| 16.10.25 | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 2 | SGX Company Announcements | ||
| 02.10.25 | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::STOCK EXCHANGE DISCLOSURE BY BIOCON LIMITED | 5 | SGX Company Announcements | ||
| 01.10.25 | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 5 | SGX Company Announcements | ||
| 18.09.25 | Biocon Biologics' Yesafili (aflibercept) Now Publicly Funded in Ontario, Canada for the Advanced Treatment of Patients with Retinal Diseases | 2 | CNW | ||
| 17.09.25 | Biocon Biologics Says FDA Approves Bosaya And Aukelso As Denosumab Biosimilars | 2 | RTTNews |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 38,870 | 0,00 % | QIAGEN N.V.: QIAGEN gibt Details zum Abschluss des synthetischen Aktienrückkaufs über bis zu rund $500 Mio. bekannt | Kapitalrückzahlung durch synthetischen Aktienrückkauf kombiniert schnelle, unmittelbare Kapitalrückzahlung an Aktionärinnen und Aktionäre mit einer Aktienzusammenlegung zur Steigerung des Gewinns... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,06 | -0,05 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| COGENT BIOSCIENCES | 34,250 | -1,41 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis | WALTHAM, Mass. and BOULDER, Colo., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 77,47 | 0,00 % | Apogee Therapeutics kündigt Zwischenergebnisse zu Asthma-Studie an | ||
| ZENAS BIOPHARMA | 16,720 | 0,00 % | Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) | - Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction in risk of IgG4-RD flare - - Obexelimab also met and demonstrated statistically... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 62,80 | -8,12 % | Genentech enters $100M deal with Structure Therapeutics for GLP-1 weight-loss drug | ||
| HARMONY BIOSCIENCES | 36,750 | 0,00 % | Harmony Biosciences Holdings, Inc.: Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress | Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that it will present data from its rare epilepsy pipeline at the 36th International Epilepsy Congress (IEC) being held August 30... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 72,37 | 0,00 % | KYMR Skyrockets 82.4% in a Year: More Upside Potential in 2026? | ||
| VERA THERAPEUTICS | 47,080 | -3,17 % | Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy | Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgANORIGIN Phase 3 trial met its primary endpoint at the prespecified interim analysis of proteinuria reduction with 46%... ► Artikel lesen | |
| NUVALENT | 97,82 | -2,99 % | Royalty Pharma plc: Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million | NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,360 | 0,00 % | JPMorgan Boosts Rating on Recursion Pharmaceuticals (RXRX) Amid AI-Driven Drug Pipeline | ||
| MINERALYS THERAPEUTICS | 35,580 | -0,36 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup | - Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful... ► Artikel lesen | |
| TREVI THERAPEUTICS | 11,360 | -4,46 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer | Experienced biotech CFO to lead financial strategy and contribute to the Company's next stage of growth
NEW HAVEN, Conn., Dec. 4, 2025 /PRNewswire/ -- Trevi Therapeutics... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 30,210 | 0,00 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| DYNE THERAPEUTICS | 18,230 | -1,46 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares | WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven... ► Artikel lesen |
BIOCON BIOLOGICS GLOBAL PLC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 100,68 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOCON BIOLOGICS GLOBAL PLC finden Sie auf Wallstreet Online.